MX2024010216A - Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico. - Google Patents

Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico.

Info

Publication number
MX2024010216A
MX2024010216A MX2024010216A MX2024010216A MX2024010216A MX 2024010216 A MX2024010216 A MX 2024010216A MX 2024010216 A MX2024010216 A MX 2024010216A MX 2024010216 A MX2024010216 A MX 2024010216A MX 2024010216 A MX2024010216 A MX 2024010216A
Authority
MX
Mexico
Prior art keywords
thienopyrrolotriazine
compounds
preparation
therapeutic use
formula
Prior art date
Application number
MX2024010216A
Other languages
English (en)
Spanish (es)
Inventor
Olivier Venier
Olivier Arnoud
Franck Caussanel
Rommel Dadji-Faihun
Gwladys Langot
Frank Marguet
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2024010216A publication Critical patent/MX2024010216A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024010216A 2022-02-21 2023-02-20 Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico. MX2024010216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22315036 2022-02-21
PCT/EP2023/054138 WO2023156643A1 (en) 2022-02-21 2023-02-20 Thienopyrrolotriazine compounds, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
MX2024010216A true MX2024010216A (es) 2024-09-02

Family

ID=81326677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010216A MX2024010216A (es) 2022-02-21 2023-02-20 Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico.

Country Status (11)

Country Link
US (1) US20250129091A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482841B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506729A (cg-RX-API-DMAC7.html)
KR (1) KR20240151767A (cg-RX-API-DMAC7.html)
CN (1) CN118843632A (cg-RX-API-DMAC7.html)
AU (1) AU2023222186A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244475A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010803A2 (cg-RX-API-DMAC7.html)
IL (1) IL314781A (cg-RX-API-DMAC7.html)
MX (1) MX2024010216A (cg-RX-API-DMAC7.html)
WO (1) WO2023156643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116375728B (zh) * 2021-12-31 2025-06-10 成都赜灵生物医药科技有限公司 噻吩吡咯并三嗪酮类化合物及其用途
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168012B2 (en) * 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
US20230203064A1 (en) * 2020-04-23 2023-06-29 Janssen Pharmaceutica Nv Tricyclic compounds as inhibitors of nlrp3

Also Published As

Publication number Publication date
EP4482841A1 (en) 2025-01-01
CO2024010803A2 (es) 2024-08-20
AU2023222186A1 (en) 2024-10-10
CA3244475A1 (en) 2023-08-24
CN118843632A (zh) 2024-10-25
WO2023156643A1 (en) 2023-08-24
JP2025506729A (ja) 2025-03-13
KR20240151767A (ko) 2024-10-18
EP4482841B1 (en) 2026-07-15
US20250129091A1 (en) 2025-04-24
IL314781A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
UY38793A (es) Compuestos químicos
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos
CO2021004789A2 (es) Piridazinonas y sus métodos de uso
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
MX2020007014A (es) Compuestos de benzamida.
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
PY2021592A (es) Arilamidinas fungicidas
CO2024010803A2 (es) Compuestos de tienopirrolotriazina, su preparación y su uso terapéutico
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
CY1112453T1 (el) Αντιϊικες ενωσεις
BR112022003982A2 (pt) Compostos heterocíclicos
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
MX387590B (es) Compuestos policíclicos como inhibidores de tirosina quinasa de bruton.
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2022002053A (es) Conjugados de il-15 y sus usos.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
BR112022003357A2 (pt) Compostos heterocíclicos
CL2021003228A1 (es) Compuestos tricíclicos y su uso
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.